Menu Back to Annual-Canadian-Meeting

Overview

October 16: Short Courses*
October 17-18: Meeting

Short Course 1: ICH, ROI, International Work Sharing
More information coming soon!

*Short Courses require separate registration.


2017 marks the sesquicentennial for Canada. Canada is celebrating 150 years of Confederation! Join us at the DIA Annual Canadian Meeting as we explore how Canada’s past has shaped the Canadian health care ecosystem of today and tomorrow. 

The DIA Annual Canadian Meeting will reflect on the evolution of Canada's health system by bringing together key thought leaders from industry, academia, regulators, and Health Canada. Expert speakers will discuss in-depth how collaboration can support new regulatory processes, innovation, and access, as well as trends in clinical research and operations, and developing transparency and engagement initiatives.

This year’s meeting will feature preconference short courses, plenary sessions, multi-track breakout sessions tailored to the beginner, intermediate, and advanced level professional, and multiple networking opportunities.
 
NEW! This year the DIA Annual Canadian Meeting will be co-located with DIA's Canadian Pharmacovigilance and Risk Management Conference. Maximize your education and time by attending both!

Approved by the Regulatory Affairs Professionals Society for 12 RAC credits.


While our meeting is currently in development, check out last year’s program to see what’s in store!
View Program.

Learning objectives

At the conclusion of this meeting, participants should be able to:

  • Describe the current and evolving regulatory environment in Canada and celebrate successes to make Canada 150
  • Learn about regulatory priorities and current topics of interest in the regulatory landscape
  • Summarize methods and approaches in various aspects of clinical trials, patient engagement, supply chain, and manufacturing
  • Discuss and learn more in-depth approaches on international harmonization, worksharing, and adoption of guidelines
  • Review and examine the various levels of transparency and postmarket activities that are underway

Program Committee

  • Marilena  Bassi, MA
    Marilena Bassi, MA Director, Therapeutic Products Directorate
    Health Canada, Canada
  • Deirdre  Cozier
    Deirdre Cozier Senior Manager, Regulatory Affairs
    Pendopharm, Division of Pharmascience, Canada
  • Loretta  Del Bosco
    Loretta Del Bosco Director, Regulatory Affairs Quality Assurance Operations
    AbbVie Corporation, Canada
  • Laura  Durno, MS, MSc
    Laura Durno, MS, MSc Acting Chief, Viral Vaccines Division
    Biologics and Genetic Therapies Directorate, Health Canada, Canada
  • Karen  Feltmate
    Karen Feltmate President
    Redstone Health Group, Inc., Canada
  • Lorella  Garofalo, PhD
    Lorella Garofalo, PhD Director, Regulatory Affairs; Worldwide Safety and Regulatory-Innovative
    Pfizer Canada Inc, Canada
  • Maggie  Graham
    Maggie Graham Senior Policy Analyst, Natural and Non-Prescription Health Products Directorate
    Health Canada, Canada
  • Keith  McIntosh
    Keith McIntosh Executive Director, Scientific & Regulatory Affairs
    Innovative Medicines Canada, Canada
  • Marc F. Poitras, PhD, MBA
    Marc F. Poitras, PhD, MBA Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
    Health Canada, Canada
  • Matthew  Ryan
    Matthew Ryan Senior Policy Analyst; Policy, Planning and International Affairs Directorate
    Health Canada, Canada
Load More

Contact us

Digital Learning Catalog

eLearning Catalog Cover
Download